Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs) for mental health conditions, announced that CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York City. The fireside chat will be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of the company's investor relations website. This appearance provides a platform for Helus Pharma to update investors on its clinical programs and strategic direction.
The announcement comes at a pivotal time for the company, which is developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, underscoring its potential to address significant unmet needs in mental health. Additionally, Helus Pharma is advancing HLP004, another proprietary NSA, in Phase 2 trials for generalized anxiety disorder. The company's pipeline also includes an extensive research portfolio of investigational NSAs, all designed to activate serotonin pathways believed to promote neuroplasticity—a mechanism that could offer durable improvements over existing treatments.
The significance of Helus Pharma's work is highlighted by the growing recognition of the limitations of current antidepressants, which often take weeks to work and may not be effective for all patients. By focusing on synthetic molecules that target serotonin receptors with high specificity, Helus Pharma aims to provide faster-acting and more effective options. The Breakthrough Therapy Designation for HLP003 signals the FDA's acknowledgment of the drug's potential to offer substantial improvement over existing therapies for MDD, a condition affecting millions worldwide.
Helus Pharma, the commercial operating name of Cybin Inc., was founded in 2019 and operates in Canada, the United States, the United Kingdom, and Ireland. The company is committed to 'helping minds heal' through the development of NSAs, which are intended to treat depression, anxiety, and other mental health conditions. With a focus on rigorous clinical development, Helus Pharma aims to bring these innovative therapies to market and improve the treatment landscape for patients who have not found relief with current options.
Investors and industry observers will be watching the H.C. Wainwright presentation closely for updates on trial progress and potential milestones. The conference provides a venue for Helus Pharma to articulate its vision and engage with the investment community. As the company advances its late-stage programs, successful outcomes could position it as a leader in the emerging field of psychedelic-inspired therapeutics, which are gaining traction for their potential to transform mental health care.
For more information about Helus Pharma and its programs, visit the company's website at www.helus.com. The company's newsroom, available at https://ibn.fm/HELP, provides the latest updates and press releases.
